Cerus (NASDAQ: CERS)
Cerus Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Cerus Company Info
Cerus Corp. engages in the research, development, and manufacturing of biomedical and surgical products. The firm produces blood system for platelets and plasma. It operates through Blood Safety segment. It markets products under the INTERCEPT brand. The company was founded by Laurence M. Corash and John E. Hearst on September 19, 1991 and is headquartered in Concord, CA.
News & Analysis
Here's Why Cerus Corporation Stock Popped Today
Preliminary third-quarter results pleased the crowd at the company's annual investor meeting.
Here's Why Cerus Corporation Stock Is Surging Today
A better-than-expected outlook after the company's first-quarter report is lifting more than spirits.
Here's Why Cerus Corporation Stock Popped Today
Positive pivotal trial results bode well for the company's new blood transfusion product.
Here's Why Cerus Corporation Rose as Much as 23.6% Today
The biopharma reported third-quarter 2017 results and additional business updates.
Why Cerus Corporation Stock Marched Higher Today
A positive regulatory development sent Cerus' shares higher today.
Here's Why Cerus Corporation Rose as Much as 17.4% Today
The company provided an update on the most pressing issue facing the biopharma stock in 2017.
Here's Why Cerus Corporation Rose as Much as 16.3% Today
Even with today's pop, the stock is near six-year lows.
Here's Why Cerus Corporation Stock Is Tanking Today
Investors headed for the exits after the company announced an unexpected product supply shortage.
Valuation
Earnings Transcripts
Cerus (CERS) Q2 2022 Earnings Call Transcript
CERS earnings call for the period ending June 30, 2022.
Cerus (CERS) Q1 2022 Earnings Call Transcript
CERS earnings call for the period ending March 31, 2022.
Cerus (CERS) Q4 2021 Earnings Call Transcript
CERS earnings call for the period ending December 31, 2021.
Cerus Corporation (CERS) Q3 2021 Earnings Call Transcript
CERS earnings call for the period ending September 30, 2021.
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.